// App-Quantinova.ai

3781 : Combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma

Researchers

Presenter

  • Lan Wei

Principal Investigators

  • Geraldine Harriman

  • Sarani Ghoshal

  • Omeed Moaven

  • Jeremy Greenwood

  • Sathesh Bhat

  • William F. Westlin

  • H. James Harwood

  • Rosana Kapeller

  • Kenneth K. Tanabe

  • Bryan C. Fuchs

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • Jounce Therapeutics, Cambridge, MA

  • Schrodinger, New York, NY.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Cirrhosis

  • Solid malignancies

Biomarkers

  • Acetyl-CoA carboxylase

Drug/Treatment

  • Sorafenib

  • ND654

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved